NEW YORK, June 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
HIV across the seven major markets is largely dominated by two companies: Gilead Sciences and ViiV Healthcare. The growing dominance of convenient one-pill once-daily regimens will increasingly pressure companies to collaborate and co-formulate their marketed and/or pipeline HIV drugs into fixed dose combinations (FDCs) to remain successful in a tight HIV market.
Features and benefits
* In-depth discussion of portfolios and strategies of key HIV companies.
* Discussion of future strategic opportunities to achieve success in a crowded HIV market.
* Review of corporate strategies in HIV.
With Gilead and ViiV Healthcare clearly dominating the HIV market, the remaining companies active in the field have much smaller HIV portfolios. An emerging HIV treatment trend towards nuc-sparing regimens offers opportunities for smaller players to form new vertical collaborations and to diversify the HIV field.
With its blockbuster products Truvada (tenofovir disoproxil fumarate/emtricita